MedKoo Cat#: 407293 | Name: NCC-149
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

NCC-149 is a HDAC8 inhibitor.

Chemical Structure

NCC-149
NCC-149
CAS#1316652-41-1

Theoretical Analysis

MedKoo Cat#: 407293

Name: NCC-149

CAS#: 1316652-41-1

Chemical Formula: C16H14N4O2S

Exact Mass: 326.0837

Molecular Weight: 326.37

Elemental Analysis: C, 58.88; H, 4.32; N, 17.17; O, 9.80; S, 9.82

Price and Availability

Size Price Availability Quantity
5mg USD 650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
NCC-149; NCC 149; NCC149.
IUPAC/Chemical Name
N-hydroxy-3-(1-((phenylthio)methyl)-1H-1,2,3-triazol-4-yl)benzamide
InChi Key
DORPIZJGSLWDIY-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H14N4O2S/c21-16(18-22)13-6-4-5-12(9-13)15-10-20(19-17-15)11-23-14-7-2-1-3-8-14/h1-10,22H,11H2,(H,18,21)
SMILES Code
O=C(NO)C1=CC=CC(C2=CN(CSC3=CC=CC=C3)N=N2)=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Certificate of Analysis
Safety Data Sheet (SDS)
Biological target:
NCC-149 is a HDAC8 inhibitor.
In vitro activity:
HDAC8-selective inhibitor (NCC-149) (HDAC8i)-treated cells showed smaller EBs than non-treated cells, as well as reduced expression levels of the neuronal marker, NeuN. Reference: Biochem Biophys Res Commun. 2018 Mar 25;498(1):45-51. https://pubmed.ncbi.nlm.nih.gov/29499194/
In vivo activity:
TBD

Preparing Stock Solutions

The following data is based on the product molecular weight 326.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
Katayama S, Morii A, Makanga JO, Suzuki T, Miyata N, Inazu T. HDAC8 regulates neural differentiation through embryoid body formation in P19 cells. Biochem Biophys Res Commun. 2018 Mar 25;498(1):45-51. doi: 10.1016/j.bbrc.2018.02.195. Epub 2018 Feb 28. PMID: 29499194.
In vitro protocol:
Katayama S, Morii A, Makanga JO, Suzuki T, Miyata N, Inazu T. HDAC8 regulates neural differentiation through embryoid body formation in P19 cells. Biochem Biophys Res Commun. 2018 Mar 25;498(1):45-51. doi: 10.1016/j.bbrc.2018.02.195. Epub 2018 Feb 28. PMID: 29499194.
In vivo protocol:
TBD
1. Identification of a Novel Aminotetralin Class of HDAC6 and HDAC8 Selective Inhibitors. By Tang, Guozhi; Wong, Jason C.; Zhang, Weixing; Wang, Zhanguo; Zhang, Nan; Peng, Zhenghong; Zhang, Zhenshan; Rong, Yiping; Li, Shijie; Zhang, Meifang; et al. From Journal of Medicinal Chemistry (2014), 57(19), 8026-8034. 2. Design, Synthesis, and Biological Activity of NCC149 Derivatives as Histone Deacetylase 8-​Selective Inhibitors. By Suzuki, Takayoshi; Muto, Nobusuke; Bando, Masashige; Itoh, Yukihiro; Masaki, Ayako; Ri, Masaki; Ota, Yosuke; Nakagawa, Hidehiko; Iida, Shinsuke; Shirahige, Katsuhiko; et al. From ChemMedChem (2014), 9(3), 657-664. 3. Rapid Discovery of Highly Potent and Selective Inhibitors of Histone Deacetylase 8 Using Click Chemistry to Generate Candidate Libraries. Suzuki, Takayoshi; Ota, Yosuke; Ri, Masaki; Bando, Masashige; Gotoh, Aogu; Itoh, Yukihiro; Tsumoto, Hiroki; Tatum, Prima R.; Mizukami, Tamio; Nakagawa, Hidehiko; et al. From Journal of Medicinal Chemistry (2012), 55(22), 9562-9575. 4. Preparation of hydroxamic acid derivatives as HDAC8 inhibitors. By Miyata, Naoki; Suzuki, Takayoshi; Ota, Yosuke; Ueda, Ryuzo; Iida, Shinsuke; Ri, Masaki. From PCT Int. Appl. (2011), WO 2011089995 A1 20110728.